Jan Nyrop Jakobsen

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. ncbi Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark Electronic address
    Eur J Cancer 49:2494-503. 2013
  2. ncbi Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark
    J Cancer Res Clin Oncol 140:645-52. 2014
  3. doi Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients
    Jan Nyrop Jakobsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark
    Cancer Chemother Pharmacol 73:43-51. 2014
  4. doi Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark
    Cancer Chemother Pharmacol 73:131-7. 2014
  5. doi Clinical impact of ki-67 labeling index in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Rigshospitalet, 9 Blegdamsvej, 2100 Copenhagen, Denmark
    Lung Cancer 79:1-7. 2013
  6. doi Irinotecan and bevacizumab in recurrent glioblastoma multiforme
    Jan Nyrop Jakobsen
    Copenhagen University Hospital, The Finsencenter, Department of Oncology, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Expert Opin Pharmacother 12:825-33. 2011
  7. doi Review on clinical trials of targeted treatments in malignant mesothelioma
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Copenhagen, Denmark
    Cancer Chemother Pharmacol 68:1-15. 2011
  8. ncbi Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
    Cancer Chemother Pharmacol 69:289-99. 2012

Detail Information

Publications8

  1. ncbi Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark Electronic address
    Eur J Cancer 49:2494-503. 2013
    ..It may also be an important factor in chemo resistance, as tumours with heterogeneous biomarker expression may potentially harbour chemo resistant tumour clones...
  2. ncbi Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark
    J Cancer Res Clin Oncol 140:645-52. 2014
    ..The current study aimed at investigating whether TS expression changes during non-pemetrexed chemotherapy of non-small cell lung cancer (NSCLC), thus making rebiopsy necessary for deciding on pemetrexed second-line treatment...
  3. doi Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients
    Jan Nyrop Jakobsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark
    Cancer Chemother Pharmacol 73:43-51. 2014
    ..Thus, the aim was to explore TUBB3 expression heterogeneity and changes during chemotherapy...
  4. doi Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark
    Cancer Chemother Pharmacol 73:131-7. 2014
    ..In addition, EGFR expression may also change during chemotherapy. The current study investigates the magnitude of these two issues...
  5. doi Clinical impact of ki-67 labeling index in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Rigshospitalet, 9 Blegdamsvej, 2100 Copenhagen, Denmark
    Lung Cancer 79:1-7. 2013
    ..A predictive impact of ki-67 to treatment in NSCLC remains unclear...
  6. doi Irinotecan and bevacizumab in recurrent glioblastoma multiforme
    Jan Nyrop Jakobsen
    Copenhagen University Hospital, The Finsencenter, Department of Oncology, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Expert Opin Pharmacother 12:825-33. 2011
    ..Although treatment with BVZ and irinotecan provides impressive response rates (RR), it is still uncertain if this treatment translates into improved clinical benefit in GBM patients...
  7. doi Review on clinical trials of targeted treatments in malignant mesothelioma
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Copenhagen, Denmark
    Cancer Chemother Pharmacol 68:1-15. 2011
    ..This article is a comprehensive review of all clinical trials evaluating the effect of targeted treatments in MM...
  8. ncbi Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
    Cancer Chemother Pharmacol 69:289-99. 2012
    ..NSCLC is highly heterogeneous and biomarker expression may vary in different areas within the same tumor. This review explores the tumor heterogeneity and chemotherapy-induced changes in EGFR biomarker status in NSCLC...